Key result
Nifedipine reduces Raynaud's phenomenon frequency and severity, while prazosin shows no benefit.
Why the study?
Does nifedipine or prazosin reduce the frequency and severity of Raynaud's phenomenon in patients with the condition?
RCT (n=15)
Double-blind
Cross-over
Does nifedipine or prazosin reduce the frequency and severity of Raynaud's phenomenon in patients with the condition?
Answers are grounded in this paper and cite their sources.
Nifedipine, but not prazosin, effectively reduces the frequency and severity of Raynaud's phenomenon.
The efficacy of nifedipine and prazosin in the treatment of Raynaud's phenomenon was assessed in a prospective double-blind randomized cross-over trial in 15 patients. Each patient received one week of nifedipine 20 mg TID, one week of prazosin 1 mg TID, and 2 weeks of placebo. Nifedipine was shown to be effective in reducing both the frequency and the severity of Raynaud's phenomenon, whereas prazosin was ineffective. Before initiation of therapy in the 15 patients, pressor responses to the intravenous alpha 1-agonist phenylephrine were assessed in the basal state, 30 min after 20 mg oral nifedipine, and 30 min after 1 mg oral prazosin; the shift to the right of the log dose-vasopressor response curves to phenylephrine was similar with nifedipine and prazosin.
No takes yet. Share an insight, caveat, or question.
Kahan et al. (1985) conducted an RCT in Raynaud's phenomenon (n=15). Nifedipine vs. Prazosin and Placebo was evaluated on Frequency and severity of Raynaud's phenomenon. Nifedipine 20 mg TID effectively reduced the frequency and severity of Raynaud's phenomenon, whereas prazosin 1 mg TID was ineffective.
Synapse has enriched 10 related papers. Consider them for comparative context: